Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EmyriaASX:EMD -2.22% Debt-to-Equity is 0.05 as of Dec. 2025, which is 67% below its 10-year median of 0.15. The stock has 1 warning sign investors should review. Among 557 Healthcare Providers & Services companies, Emyria ranks better than 86.18% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Emyria's Debt-to-Equity or its related term are showing as below:
ASX:EMD'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.15 Max: 3.12
Current: 0.05
During the past 7 years, the highest Debt-to-Equity Ratio of Emyria was 3.12. The lowest was 0.05. And the median was 0.15.
ASX:EMD's Debt-to-Equity is ranked better than 86.18% of 557
companies
in the Healthcare Providers & Services industry
Industry Median: 0.41
vs ASX:EMD: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Emyria Debt-to-Equity Related Terms
Emyria Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Emyria's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EMD vs VEEV, BTSG, TEM: Debt-to-Equity Comparison
For the Health Information Services subindustry, Emyria's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emyria Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Emyria's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Emyria's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emyria (ASX:EMD) has a Debt-to-Equity of 0.05 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Emyria and its competitors. This is 67% below median its historical median of 0.15. Over the past decade, Emyria's Debt-to-Equity has ranged from 0.05 to 3.12. According to the industry distribution chart, Emyria ranks #77 out of 557 companies in the Healthcare Providers & Services industry, placing it in the top 13.8%.
Is Emyria's Debt-to-Equity too high?
Emyria's current Debt-to-Equity of 0.05 is 67% below median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 3.12. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. Emyria's value of 0.05 is 87.8% below this industry median. Based on the distribution chart, Emyria ranks #77 out of 557 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Emyria's Debt-to-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Emyria ranks #77 out of 557 companies for Debt-to-Equity. This places Emyria in the top 14% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.41. Emyria's value of 0.05 is 87.8% below this benchmark. Historically, Emyria's own Debt-to-Equity has ranged from 0.05 to 3.12 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.41, Emyria has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emyria's current Debt-to-Equity of 0.05 is 87.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Emyria and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emyria's current Debt-to-Equity is 0.05, which is 67% below median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.04 — trading 46.7% above its estimated fair value. The current Debt-to-Equity is 0.05, which is 67% below median its 10-year median of 0.15 and 87.8% below the Healthcare Providers & Services industry median of 0.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Debt-to-Equity is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EMD has been successfully added to your 
